Literature DB >> 12505680

Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients.

Ezra Mulugeta1, Evert Karlsson, Atiqul Islam, Raj Kalaria, Halinder Mangat, Bengt Winblad, Abdu Adem.   

Abstract

We assessed muscarinic M(1), M(2) and M(4) receptor subtypes in the hippocampus of Alzheimer's and control brains by receptor autoradiography using ligands such as [(125)I]muscarinic toxin-1 ([(125)I]MT-1, M(1) selective), [(3)H]AFDX-384 (M(2) partially selective) and [(125)I]muscarinic toxin 4 ([(125)I]M(4) toxin-1, M(4) selective). Our results revealed a significant decrease in muscarinic M(4) receptor binding in the dentate gyrus and CA4 regions of brain sections from Alzheimer's patients compared to controls. No changes in the density of M(1) or M(2) receptor binding were observed. Our findings suggest that, relative to other muscarinic receptor subtypes, the M(4) receptor could be the subtype which is selectively compromised in Alzeheimer's disease (AD).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12505680     DOI: 10.1016/s0006-8993(02)03542-4

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  20 in total

1.  FGWAS: Functional genome wide association analysis.

Authors:  Chao Huang; Paul Thompson; Yalin Wang; Yang Yu; Jingwen Zhang; Dehan Kong; Rivka R Colen; Rebecca C Knickmeyer; Hongtu Zhu
Journal:  Neuroimage       Date:  2017-07-20       Impact factor: 6.556

Review 2.  Alzheimer disease.

Authors:  Rudy J Castellani; Raj K Rolston; Mark A Smith
Journal:  Dis Mon       Date:  2010-09       Impact factor: 3.800

3.  Properties of glutamate receptors of Alzheimer's disease brain transplanted to frog oocytes.

Authors:  Annalisa Bernareggi; Zulma Dueñas; Jorge Mauricio Reyes-Ruiz; Fabio Ruzzier; Ricardo Miledi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-14       Impact factor: 11.205

4.  Temporal and region-dependent changes in muscarinic M4 receptors in the hippocampus and entorhinal cortex of adrenalectomized rats.

Authors:  Ezra Mulugeta; Irwin Chandranath; Evert Karlsson; Bengt Winblad; Abdu Adem
Journal:  Exp Brain Res       Date:  2006-05-05       Impact factor: 1.972

5.  Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs.

Authors:  Joseph A Araujo; Nigel H Greig; Donald K Ingram; Johan Sandin; Christina de Rivera; Norton W Milgram
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 6.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

7.  Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease.

Authors:  Elizabeth Scarr; Catriona McLean; Brian Dean
Journal:  J Neural Transm (Vienna)       Date:  2016-09-29       Impact factor: 3.575

8.  Microtransplantation of functional receptors and channels from the Alzheimer's brain to frog oocytes.

Authors:  R Miledi; Z Dueñas; A Martinez-Torres; C H Kawas; F Eusebi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-28       Impact factor: 11.205

Review 9.  M1 muscarinic acetylcholine receptor in Alzheimer's disease.

Authors:  Shangtong Jiang; Yanfang Li; Cuilin Zhang; Yingjun Zhao; Guojun Bu; Huaxi Xu; Yun-Wu Zhang
Journal:  Neurosci Bull       Date:  2014-03-03       Impact factor: 5.203

10.  Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease.

Authors:  Katy A Chalmers; Gordon K Wilcock; Harry V Vinters; Elaine K Perry; Robert Perry; Clive G Ballard; Seth Love
Journal:  J Neurol       Date:  2009-02-25       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.